Digital Health Funding Stays Robust as Capital Concentrates in AI-Native Platforms

Digital health fundraising continues at a steady clip, with September rounds spanning pre-seed clinical infrastructure plays to a $220 million growth round for a medical imaging network. The pattern across recent weeks is consistent: capital is flowing toward companies that pair AI with clinical oversight, and toward platforms that can demonstrate measurable revenue or cost impact rather than promise it.

Canadian virtual care startup Blair Health raised 4.24 million Canadian dollars in a pre-seed round led by the Business Development Bank of Canada's Thrive Venture Fund, alongside Accelia Capital, Ogaei Investments, the Ontario Centre of Innovation and angel investors. Blair's model encodes specialist assessment logic, protocols and escalation triggers into software, letting in-house nurse practitioners and family doctors deliver specialty-level care with subspecialist oversight for complex cases. The company operates in seven U.S. states today, sold both direct to consumer and through employers, and plans expansion across Canada and the U.S.

"The clinician always makes the final decision; Blair gives them specialist-level structure to do it," said Madge Rumman, Blair co-founder and CEO. The company currently covers menopause, urology, pelvic health, clinical nutrition and weight management, a narrow but clinically dense set of specialties where wait times for human specialists are notoriously long.

At the other end of the funding spectrum, radiology startup Epsilon Health emerged from stealth with $27.6 million from AlleyCorp, Uncork Capital, Renegade Partners, SemperVirens and Jack Altman. The company says it is already processing thousands of imaging studies daily for some of the largest imaging providers in the country, less than ten months after founding. That pace of scale, if accurate, is unusual and worth watching as a signal of how quickly AI-native clinical practices can displace legacy radiology groups.

AI Infrastructure Draws the Largest Checks

The biggest rounds this cycle went to companies solving infrastructure and access problems rather than pure clinical delivery. Forus, an AI-powered medication access platform, closed a $150 million Series C led by Bain Capital Ventures just four months after a $160 million Series B, pushing its valuation to $3 billion. The company says it now reaches 85% of U.S. residential zip codes and serves practices in all 50 states. Back-to-back raises of that size in under half a year suggest investors are betting aggressively on medication access as a durable category, not simply chasing a single hot deal.

Scan.com, which is building what it calls the largest medical imaging network in the U.S., raised $220 million in a Series C round combined with debt facilities from Noteus Partners, Aviva, Concord Health Partners, YZR Capital, Oxford Capital and others, with debt provided by VerisFi Capital and Atempo Growth. The company says revenue has doubled over the past year to a $165 million annualized run rate, with more than 900,000 patients served globally. Verily, meanwhile, extended its March fundraising with new investment from NVIDIA and existing backer CU Healthcare Innovation Fund, though the amount was undisclosed. The involvement of a chip maker rather than a traditional health investor is notable, and it underscores how central compute infrastructure has become to the AI-healthcare thesis.

Cardiac monitoring company Implicity raised $40 million led by IRIS with participation from Five Arrows to scale its platform, which already monitors more than 120,000 patients daily across the U.S., France and Germany. GenHealth.ai closed a $16.5 million Series A led by Flare Capital Partners, with backers including Craft Ventures, Obvious Ventures, Eniac Ventures, InHealth Ventures, Epsilon Health Investors and ARTIS, to expand its back-office AI agents. The company claims providers using its tools get paid over 30% more, an outcome CEO Ricky Sahu called "virtually unheard of in RCM." GenHealth.ai has now raised $30 million total.

Revenue cycle automation drew another notable check: Arintra, an AI-driven medical coding platform, raised a $25 million Series B led by Define Ventures, bringing its total to $51 million. The company reports a 5.1% increase in compliant revenue capture, a 32% reduction in cost and a 43% decrease in coding-related denials for customers, figures that, if independently verified, would justify the investor interest in RCM automation as a category with clear, quantifiable ROI.

Not every round centered on AI. Thyme Care, a value-based oncology company, raised $125 million in a Series E backed by JPMorgan's Morgan Health, Humana and CVS Health Ventures. The funding will support a new parent structure, Thyme Companies, aimed at broader cancer care problems including biosimilar adoption and clinical trial accrual. Thyme Care now serves 10.5 million people and manages more than $7 billion in oncology spending. OmicsBank, a clinical data infrastructure company operating across Asia, raised a modest $2.25 million seed from Redesign Health to expand into the U.S. and grow its dataset, which already includes EHR data from 12.5 million patients and 30 million DICOM images. On the consumer side, period care brand Viv raised $2 million from Launchpad Venture Group and other angel investors to expand its toxin-free tampon line into Whole Foods, bringing its total raised to $3.3 million, a reminder that not all digital health capital is chasing AI.

What Investors Should Watch

The spread between round sizes tells its own story. Pre-seed and seed checks in the low single-digit millions are going to narrowly scoped clinical or data plays, while growth-stage rounds of $100 million or more are concentrating in companies with proven scale metrics, whether that's Forus's zip code coverage, Scan.com's run rate or Thyme Care's oncology spend under management. Investors should watch whether claimed efficiency gains, like Arintra's coding accuracy figures or GenHealth.ai's 30% reimbursement lift, hold up as these companies scale beyond early customer cohorts. Repeat, rapid-fire raises such as Forus's two rounds in four months also warrant scrutiny: they can signal genuine demand outpacing supply of capital, or they can mask burn rates that outstrip revenue growth. Either way, the throughline across this batch of deals is clear: capital is rewarding demonstrable outcomes over narrative alone.